Multi-target angiogenesis inhibitor combined with PD-1 inhibitors may benefit advanced non-small cell lung cancer patients in late line after failure of EGFR-TKI therapy-MedSci.cn

Multi-target angiogenesis inhibitor combined with PD-1 inhibitors may benefit advanced non-small cell lung cancer patients in late line after failure of EGFR-TKI therapy

Yu, L; Hu, YH; Xu, JL; Qiao, R; Zhong, H; Han, BH; Xia, JJ; Zhong, RB

Xia, JJ; Zhong, RB (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm Med, Sch Med, Huaihai West Rd 241, Shanghai 200030, Peoples R China.

INTERNATIONAL JOURNAL OF CANCER, 2023; 153 (3): 635

Abstract

Treatments for NSCLC patients with EGFR-TKI resistance are limited. Given that immunotherapy and antiangiogenic agents may have synergistic antitumor ......

Full Text Link